Janux Therapeutics Files Q1 2025 10-Q
Ticker: JANX · Form: 10-Q · Filed: May 8, 2025 · CIK: 1817713
| Field | Detail |
|---|---|
| Company | Janux Therapeutics, Inc. (JANX) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, equity, securities
TL;DR
Janux Q1 10-Q filed. Equity, stock options, and fair value data updated.
AI Summary
Janux Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including details on its equity incentive plans and stock options. Key financial data points such as Additional Paid-In Capital and Fair Value Inputs for various securities were disclosed.
Why It Matters
This filing provides investors with an update on Janux Therapeutics' financial health and equity structure, crucial for understanding the company's operational status and potential for future growth.
Risk Assessment
Risk Level: medium — The filing contains standard financial disclosures for a public company, but the nature of biotech and pharmaceutical development inherently carries significant risks.
Key Numbers
- 2025-03-31 — Reporting Date (End of the fiscal quarter for this 10-Q filing.)
- 2025-01-01 — Period Start Date (Beginning of the reporting period for RSU activity.)
- 2017-08-01 — Plan Adoption Date (Start date associated with the 2017 Equity Incentive Plan.)
Key Players & Entities
- Janux Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — Period of report for the 10-Q
- 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO, CA 92130 (address) — Business and Mail Address
- us-gaap:AdditionalPaidInCapitalMember (financial_metric) — Reported financial item
- us-gaap:FairValueInputsLevel1Member (financial_metric) — Fair value input level disclosed
- us-gaap:FairValueInputsLevel2Member (financial_metric) — Fair value input level disclosed
- us-gaap:USTreasurySecuritiesMember (security) — Type of security with fair value inputs
- janx:SharesAvailableForIssuanceUnderESPPMember (equity_metric) — Shares available under ESPP
- janx:RestrictedStockUnitsRSUMember (equity_metric) — Restricted Stock Units
- janx:TorreyPlazaMember (location) — Specific location mentioned
FAQ
What was the total Additional Paid-In Capital as of March 31, 2025?
The filing indicates 'us-gaap:AdditionalPaidInCapitalMember' was reported for March 31, 2025, but the specific dollar amount is not provided in this excerpt.
What types of securities had their fair value inputs categorized as Level 1 and Level 2 as of March 31, 2025?
As of March 31, 2025, US Treasury Securities ('us-gaap:USTreasurySecuritiesMember') and US Agency Bonds ('janx:USAgencyBondsMember') had their fair value inputs categorized as Level 1 and Level 2.
When was the Janux Therapeutics, Inc. 2017 Equity Incentive Plan adopted?
The 'janx:TwoThousandSeventeenEquityIncentivePlanMember' is associated with dates starting from August 1, 2017.
What is the company's business address?
The business address for Janux Therapeutics, Inc. is 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO, CA 92130.
What was the filing date for this 10-Q report?
This 10-Q report was filed on May 8, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Janux Therapeutics, Inc. (JANX).